Abstract
Additional tocilizumab treatment led to improvement in patients with mild/moderate rheumatoid arthritis. The study results give no indication that the combination of Tocilizumab with Methotrexate induces a better outcome (preserving the level of disease activity achieved at week 12) in comparison with Tocilizumab monotherapy in patients corresponding to those included into the study.
Highlights
As data on the efficacy of biologics in patients with mild/moderate rheumatoid arthritis are limited, this study was performed to assess the efficacy and safety of tocilizumab plus methotrexate versus tocilizumab monotherapy on disease activity
Additional tocilizumab treatment led to improvement in patients with mild/moderate rheumatoid arthritis
The study results give no indication that the combination of Tocilizumab with Methotrexate induces a better outcome in comparison with Tocilizumab monotherapy in patients corresponding to those included into the study
Summary
As data on the efficacy of biologics in patients with mild/moderate rheumatoid arthritis are limited, this study was performed to assess the efficacy and safety of tocilizumab plus methotrexate versus tocilizumab monotherapy on disease activity. There have been major advances in the treatment of rheumatoid arthritis (RA) [1]. While early diagnosis and treatment of the disease have added to improved outcomes, biologic agents provide improved efficacy in an additional number of patients compared to traditional treatments [2]. Despite these advances, approximately 30 to 40% of patients fail to achieve an acceptable clinical response or to tolerate the new agents [3]. A considerable percentage of patients fail to respond to these therapies [6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
